PIONEER 6

The PIONEER 6 CVOT assessed the cardiovascular safety of oral semaglutide in patients with type 2 diabetes at high risk of CV events. This module details the results.

PIONEER 6
Rate this content
  • PIONEER 6
  • PIONEER 6
  • PIONEER 6
  • PIONEER 6: trial design
  • PIONEER 6: key inclusion and exclusion criteria
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go